|
||
| |||||||
|
Anti-angiogenic activity of SR 25989 Between 1970 and 1994, cancer claimed the lives of about 0.5 million Americans every year. Although mortality levels remain massive, the incidence of cancer related death is gradually diminishing due to improved detection and greater therapeutic options. Angiogenesis inhibitors have attracted considerable attention in this respect and this therapeutic class is anticipated to represent a major arm of anti-cancer therapy. Indeed by 2006, the market for all angiogenesis regulating products is likely to reach $1.75 billion. One exciting molecule in development is the thienopyridine SR 25989, an enantiomer of the anti-aggregant clopidogrel (Plavix). SR 25989 lacks anti-aggregant activity but inhibits endothelial cell proliferation in vitro by increasing the expression of endogenous thrombospondin-1, a natural potent inhibitor of angiogenesis. The anti-angiogenic effect of SR 25989 has been investigated both in vitro and in vivo and has been shown to reduce spontaneous and platelet derived growth factor induced angiogenesis. In vivo, SR 25989 reduced the number and size of lung metastases and abolished neovascularisation in residual metastases. The potent anti-angiogenic properties SR 25989 are thus confirmed and studies investigating the ability of this molecule or it's derivatives to inhibit metastatic dissemination in humans are eagerly awaited. Link to journal abstract:
Interested in collaborating with this group? Contact leaddiscovery@bioportfolio.co.uk LeadDiscovery and BioPortfolio aims to provide reliable, insightful analysis on the biotechnology industry. However, this information is provided "as is" and no representations or warranties either express or implied of completeness, accuracy, or of any other nature are made with respect to this information. This information is neither an offer to sell nor a solicitation to buy the securities of any company. This information contains forward-looking statements, which involve risks and uncertainties which may not be listed. The biotechnology industry is an emerging industry and the securities of the companies mentioned in this report have a very high degree of risk and volatility. For this reason, this information is supplied on the condition that the reader will make his or her own determination as to its suitability for any purpose prior to any use of this information. The employees and officers of LeadDiscovery and BioPortfolio may hold positions in some or all of the stocks discussed in this report. This abstract has been produced by LeadDiscovery Ltd. Founded by life scientists for life scientists we aim to help industry identify cutting edge drug discovery options and academic/biotech institutions maximize the potential of their research. Abstracts strictly reflect the opinion of LeadDiscovery's editorial panel. While all reasonable efforts are made to ensure the accuracy of information provided LeadDiscovery and the publisher BioPortfolio, takes no responsibility for incorrect or misleading information. LeadDiscovery is designed for educational and drug development purposes only and is not intended or designed to offer medical advice or advice of any sort, and must not be used for such purpose. The information provided through LeadDiscovery and BioPortfolio should not be used for diagnosing or treating a health problem or a disease and no reliance should be placed on any information contained in this abstract or elsewhere on LeadDiscovery's and BioPortfolio's website. It is not intended to be a substitute for professional care. If you have or suspect you may have a health problem, you should consult your physician or other health care provider. |
|
| ||||||||
